Ipca Laboratories Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/as-770041f88e9258419165e408.pdf

Key Takeaways


Domestic Formulations

Jain: "So on continuous basis, both our portfolio of rheumatoid arthritis and osteoarthritis, which includes Xerodol and all rheumatoid arthritis products, that has- they are continuously performing and continuously growing in the range of around 14 to 15% kind of range. So we have absolutely no concern on that. And in fact, from current Rs 1,500 crore of Umbrella brand, we are looking, uh, similar kind of growth to continue for next, uh, 3-4 years."

Export Formulations

Jain: "But because of that kind of scenario, there are lots of disturbance in UK market today, uh, that a lot of products are going in short supplies and all, and prices are returning back because situation of selling product at lower price cannot continue for long."

Unichem Performance


Margins & Balance Sheet

Jain: "Every year we should be improving by by almost around 1 percent to 1.25 percent of EBITDA on consolidated basis, and IPCA EBITDA will go by almost around 1.5 percent standalone EBITDA."

Subsidiaries


Guidance & Commitments

CommitmentSpecificsTimeline
Overall revenue growth14–16% (revised from 12–13%)FY27
Consolidated EBITDA margin22–23%FY27
Medium-term consolidated EBITDA improvement~1% to 1.25% per yearMedium-term, annual
Medium-term standalone EBITDA improvement~1.5% per yearMedium-term, annual
Zerodol umbrella brand growth14–15% range sustainedNext 3–4 years
Institutional business revenue₹325–340 cr (above earlier ₹300 cr guidance)FY27
Branded business growth15–16%FY27
Unichem EBITDA margin11–13% if freight/energy costs remain highOngoing
Rupee term loanClose year at ~₹70–75 crFY27
Piska subsidiary improvementProfitability improvementNext financial year

Key Metrics

MetricQ2 FY27
Consolidated revenue₹2,910 cr, +14% YoY from ₹2,557 cr
Consolidated EBITDA margin22.97%, improved from 21.68% in Q2 FY26
Standalone EBITDA margin26.61%, improved from 25.46% in Q2 FY26
Domestic formulation revenue₹1,157 cr, +14% YoY from ₹1,019 cr
Export formulation revenue (standalone)₹653 cr, +32% YoY from ₹493 cr
Promotional branded business revenue (ROW)₹172 cr, +19% YoY from ₹145 cr
Generic market revenue (ex-tender)₹364 cr, +36% YoY from ₹268 cr
Institutional generic business growth~45% YoY
API growth~6% YoY
Pain segment revenue₹628 cr, +16% YoY from ₹543 cr
Zerodol umbrella brand sales (IQVIA, September 2026)₹1,500 cr, 4th largest brand in IPM
IPCA market share (IQVIA, September 2026)2.11%, up from 2.09% in September 2026
Unichem EBITDA margin11.3%, freight costs rose by ₹31.2 cr in other expenses
Unichem US portfolio sales$38.5 million for the quarter
IPCA portfolio US sales (booked in Unichem)$5.8 million for the quarter
Cash on books~₹700 cr
Rupee term loan borrowing~₹155 cr, expected to close year at ₹70–75 cr